Search
Research
TLR3 and RIG-I gene variants: Associations with functional effects on receptor expression and responses to measles viruMeasles virus causes severe morbidity and mortality, despite the availability of measles vaccines. Successful defence against viral pathogens requires early...
Research
Predominance of nontypeable haemophilus influenzae in children with otitis mediaIn Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Research
Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell toleranceConcerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...
Research
Slam and dc-sign measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccineDespite the use of measles vaccine, measles virus continues to circulate and cause severe disease
Research
TLR1/2 activation during Heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T cell responses providingLeishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species
Research
Immediate and Longer Term Immunogenicity and Safety of a Single Dose of the Combined Haemophilus influenzae TypeHib-primed but MenC-naive toddlers (N = 433) were randomized to receive 1 dose of Hib-MenC-TT or separate Hib-TT and MenC-CRM197 vaccines.
Research
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papilloma VirusWe conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys...
Research
Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.
Research
Nudging towards COVID-19 and influenza vaccination in children with medically at-risk conditionsNon-coercive 'nudge' interventions have shown the potential to promote health behaviours. This study aimed to evaluate the impact of nudge interventions on COVID-19/influenza vaccine uptake among children with medically at-risk conditions.
Research
Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 yearsRespiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.